MicroRNA and Heart Failure
AbstractHeart failure (HF) imposes significant economic and public health burdens upon modern society. It is known that disturbances in neurohormonal status play an important role in the pathogenesis of HF. Therapeutics that antagonize selected neurohormonal pathways, specifically the renin-angiotensin-aldosterone and sympathetic nervous systems, have significantly improved patient outcomes in HF. Nevertheless, mortality remains high with about 50% of HF patients dying within five years of diagnosis thus mandating ongoing efforts to improve HF management. The discovery of short noncoding microRNAs (miRNAs) and our increasing understanding of their functions, has presented potential therapeutic applications in complex diseases, including HF. Results from several genome-wide miRNA studies have identified miRNAs differentially expressed in HF cohorts suggesting their possible involvement in the pathogenesis of HF and their potential as both biomarkers and as therapeutic targets. Unravelling the functional relevance of miRNAs within pathogenic pathways is a major challenge in cardiovascular research. In this article, we provide an overview of the role of miRNAs in the cardiovascular system. We highlight several HF-related miRNAs reported from selected cohorts and review their putative roles in neurohormonal signaling. View Full-Text
Share & Cite This Article
Wong, L.L.; Wang, J.; Liew, O.W.; Richards, A.M.; Chen, Y.-T. MicroRNA and Heart Failure. Int. J. Mol. Sci. 2016, 17, 502.
Wong LL, Wang J, Liew OW, Richards AM, Chen Y-T. MicroRNA and Heart Failure. International Journal of Molecular Sciences. 2016; 17(4):502.Chicago/Turabian Style
Wong, Lee L.; Wang, Juan; Liew, Oi W.; Richards, Arthur M.; Chen, Yei-Tsung. 2016. "MicroRNA and Heart Failure." Int. J. Mol. Sci. 17, no. 4: 502.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.